The 36th Congress of the European Society of
Clinical Microbiology and Infectious Diseases (ESCMID Global 2026)

People living with HIV-1 (PLWH) who discontinued traditional non-nucleoside reverse transcriptase inhibitor (NNRTI)- and boosted integrase strand transfer inhibitor (INSTI)-based regimens have maintained viral suppression following their switch to the next-generation NNRTI ainuovirine coformulated with lamivudine and tenofovir DF (ANV/3TC/TDF), as shown by the 144-week open-label results from the SPRINT* post-study presented at ESCMID Global 2026.

Treatment with colchicine and famotidine plus loratadine, in addition to specialist supportive care, can substantially ease severe fatigue among patients suffering from long COVID, as shown by the results of the STIMULATE ICP trial.

A large real-world study presented at ESCMID Global 2026 shows that maternal respiratory syncytial virus (RSV) vaccination reduces the risk of hospitalization in young infants.

Part 2 of the HAPPEN* trial shows a 60-percent reduction in the incidence of non-ventilator–associated hospital-acquired pneumonia (NV-HAP) among hospitalized patients with improved oral hygiene.